Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Vasculitis
•
GCA
•
Large vessel vasculitis
What is your approach to patients with GCA who have difficulty with prednisone weaning (20mg) despite use of tocilizumab?
Is there benefit of addition of a DMARD such as methotrexate? Would you revisit diagnosis?
Related Questions
Would you add a DMARD such as methotrexate for a patient with GCA and partial response to tocilizumab but inability to taper prednisone below 10mg daily?
What biologic or conventional/synthetic DMARD would you use as a steroid sparing agent in a patient with GCA and a history of diverticulitis?
What is your approach to treating IgA nephropathy in patients who also have IgA vasculitis?
How would you approach management of a young woman referred for isolated anterior uveitis (now resolved), in the absence of systemic manifestations or end-organ involvement, but with serologies notable for strongly positive PR3 (negative c-ANCA)?
When screening for malignancy, do you order CT with contrast (or) both with and without contrast?
How would you counsel a woman with a strong family history of thrombosis about oral contraceptives?
How do you approach hypogammaglobulinemia in a patient with sarcoidosis?
How do you decide when to use acid-suppressive medications for GI prophylaxis when patients are on prolonged corticosteroid therapy?
How would you approach an 80 year old patient with a history of pericardial effusion causing pericardial tamponade with peripheral eosinophilia, pANCA 1:1280 and MPO 139 but no other vasculitic phenomenon/renal dysfunction?
Do you have safety concerns when prescribing GLP-1 medications in patients on corticosteroids or immunosuppressive therapy?